Celebrex (Celecoxib)



Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 42.9%
Ill-defined Disorder 42.9%
Arthritis 14.3%
Malabsorption 25.0%
Myocardial Infarction 25.0%
Thrombosis 25.0%
Vomiting 25.0%
Secondary
Product Used For Unknown Indication 22.4%
Osteoarthritis 14.9%
Arthritis 10.4%
Pain 7.5%
Diabetes Mellitus 6.0%
Hypertension 6.0%
Blood Cholesterol Increased 4.5%
Arthralgia 3.0%
Depression 3.0%
Gait Disturbance 3.0%
Herpes Zoster 3.0%
Paraesthesia 3.0%
Rheumatoid Arthritis 3.0%
Back Pain 1.5%
Bladder Disorder 1.5%
Blood Cholesterol Abnormal 1.5%
Constipation 1.5%
Contraception 1.5%
Convulsion 1.5%
Erectile Dysfunction 1.5%
Renal Failure Acute 14.3%
Bradycardia 4.8%
Drug Ineffective 4.8%
Escherichia Infection 4.8%
Foot Operation 4.8%
Gait Disturbance 4.8%
Hypertension 4.8%
Off Label Use 4.8%
Pain 4.8%
Pruritus 4.8%
Rash 4.8%
Respiratory Arrest 4.8%
Therapy Cessation 4.8%
Treatment Noncompliance 4.8%
Tremor 4.8%
Urethral Prolapse 4.8%
Urinary Tract Infection 4.8%
Vulva Cyst 4.8%
Weight Increased 4.8%
Concomitant
Osteoporosis 18.4%
Multiple Sclerosis 12.8%
Product Used For Unknown Indication 11.2%
Plasma Cell Myeloma 10.4%
Osteoporosis Prophylaxis 9.6%
Prostate Cancer Metastatic 4.0%
Actinic Keratosis 3.2%
Chronic Myeloid Leukaemia 3.2%
Gait Disturbance 3.2%
Immunodeficiency Common Variable 3.2%
Osteopenia 3.2%
Acromegaly 2.4%
Depression 2.4%
Medulloblastoma 2.4%
Non-hodgkin's Lymphoma 2.4%
Bone Cancer 1.6%
Colonoscopy 1.6%
Constipation 1.6%
Diabetes Mellitus 1.6%
Myelodysplastic Syndrome 1.6%
Stress Fracture 21.6%
Urinary Tract Infection 9.8%
Nausea 5.9%
Rash 5.9%
Weight Decreased 5.9%
Death 3.9%
Diverticulitis 3.9%
Headache 3.9%
Heart Rate Decreased 3.9%
Incorrect Drug Administration Duration 3.9%
Neutropenia 3.9%
Pain In Extremity 3.9%
Renal Impairment 3.9%
Syncope 3.9%
White Blood Cell Count Decreased 3.9%
Wrong Technique In Drug Usage Process 3.9%
Anaphylactic Reaction 2.0%
Application Site Swelling 2.0%
Atrial Fibrillation 2.0%
Bladder Transitional Cell Carcinoma 2.0%